Azenta (AZTA) just released quarterly results that showed meaningful gains in both revenue and profitability compared to last year. The company also set expectations for continued organic growth into ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the ...

Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, March 8 [May 8], 2024. I will now turn ...

Looking ahead to fiscal year 2026, Azenta provided guidance for organic revenue growth of 3% to 5% year-over-year, with low-single-digit growth expected in Multiomics and mid-single-digit growth ...

Earnings call Azenta reported Q4 FY25 revenue of $159M (+6% YoY, +4% organic), with adjusted EBITDA margin of 13% and EPS of $0.21. FY25 revenue grew 4% YoY to $594M, and adjusted EBITDA margin ...

Forward Guidance Looking ahead, Azenta provided fiscal year 2025 guidance that excludes B Medical Systems. The company projects organic revenue growth of 3% to 5% year-over-year, with Multiomics ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Azenta, Inc.